COMP <GO>
DNTH vs PTCT // PIOTROSKI F-SCORE QUALITY
Dianthus Therapeutics Inc. (NASDAQ) VS. PTC Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DNTH 2
— PTCT 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: PTCT
LAST: $82.25 (-0.16%) • MKT CAP: $4.61B
piotroski-score
4/9
LAST: $60.88 (+1.52%) • MKT CAP: $5.01B
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DNTH VS. PTCT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DNTH | PTCT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.70% | 85.00% | -115.70 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 6.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.79% | 13.05% | -15.84 | PTCT | /fcf-yield <GO> |
| Operating Margin | -60.00% | 50.10% | -110.10 | PTCT | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 39.50% | -99.50 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 114.50% | -179.50 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 1.73 | +24.27 | DNTH | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 9/9 | -5.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.8 | 43.2 | +3.60 | DNTH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 6.6x | +13.40 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.61B | $5.01B | -$402.3M | PTCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DNTH REV | PTCT REV | DNTH GROSS % | PTCT GROSS % | DNTH FCF | PTCT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.0M | $1.73B | — | — | -$129.2M | $702.3M |
| FY 2024 | $6.2M | $806.8M | — | — | -$78.5M | -$114.2M |
| FY 2023 | $2.8M | $937.8M | — | — | -$37.0M | -$200.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DNTH // BETA 1.08
PTCT // BETA 1.15